Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 10/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21058080 | 0.84 | CTSD (0.45) | CTSD | |
| SCHEMBL21058081 | 0.84 | CTSD (0.45) | CTSD | |
| SCHEMBL21103726 | 0.84 | CTSD (0.45) | CTSD | |
| SCHEMBL21058082 | 0.84 | CTSD (0.45) | CTSD | |
| SCHEMBL10618713 | 0.77 | MC4R (0.43) | CTSDCYP3A4TSHRHSD17B10ALDH1A1 | |
| SCHEMBL21057643 | 0.75 | CTSD (0.44) | CTSD | |
| SCHEMBL21057644 | 0.75 | CTSD (0.44) | CTSD | |
| SCHEMBL21057955 | 0.75 | CYP2D6 (0.50) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL6976103 | 0.74 | CTSD (0.49) | CTSD | |
| SCHEMBL6976101 | 0.74 | CTSD (0.49) | CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344605-B2 | Substituted pyrrolidine amides II | GRUENENTHAL GMBH (DE) | 2025-07-01 | — | — | US | disclosed |
| US-20220127264-A1 | SUBSTITUTED PYRROLIDINE AMIDES II | GRUENENTHAL GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| US-20220127264-A1 | SUBSTITUTED PYRROLIDINE AMIDES II | GRUENENTHAL GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| EP-3728233-B1 | SUBSTITUTED PYRROLIDINE AMIDES II | GRUENENTHAL GMBH (DE) | 2022-04-20 | — | — | EP | disclosed |
| EP-3728233-B1 | SUBSTITUTED PYRROLIDINE AMIDES II | GRUENENTHAL GMBH (DE) | 2022-04-20 | — | — | EP | disclosed |
| EP-3728233-A1 | SUBSTITUTED PYRROLIDINE AMIDES II | Grünenthal GmbH (DE) | 2020-10-28 | — | — | EP | disclosed |
| CN-111491931-A | Substituted pyrrolidine amides II | 格吕伦塔尔有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20190185470-A1 | Substituted Pyrrolidine Amides II | GRUENENTHAL GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
| US-20190185470-A1 | Substituted Pyrrolidine Amides II | GRUENENTHAL GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185470-A1 | Substituted Pyrrolidine Amides II | NR3C1, NR3C2, MC2R | CTSD 4156/4885CYP3A4 697/4885CYP1A2 188/4885 |
| US-20220127264-A1 | SUBSTITUTED PYRROLIDINE AMIDES II | NR3C1, NR3C2, MC2R | CTSD 4156/4885CYP3A4 697/4885CYP1A2 188/4885 |
| US-12344605-B2 | Substituted pyrrolidine amides II | NR3C1, NR3C2, MC2R | CTSD 4156/4885CYP3A4 697/4885CYP1A2 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.